Advertisement
Xalkori, which is also called crizotinib, is a drug that treats non-small cell lung cancer (NSCLC) after it has spread to other parts of the body.
Before Xalkori is prescribed, patients take a test to determine if they have changes in a certain gene, the anaplastic lymphoma kinase gene. The drug attacks the proteins produced by these mutations, so it's given only to those who test positive -- an estimated at 1% to 7% of NSCLC sufferers.
Before Xalkori is prescribed, patients take a test to determine if they have changes in a certain gene, the anaplastic lymphoma kinase gene. The drug attacks the proteins produced by these mutations, so it's given only to those who test positive -- an estimated at 1% to 7% of NSCLC sufferers.
Continue Learning about Pharmacology
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.